Martin Holst Lange
Martin Holst Lange is the head of development at Novo Nordisk, a global healthcare company known for its innovations in diabetes and obesity treatments. Recently, he announced that the company will explore the potential of its GLP-1 obesity drugs to assist patients struggling with addiction, emphasizing the need for rigorous scientific and regulatory investigation into this promising area.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.
7
Ireland:
Martin Holst Lange, head of development at Novo Nordisk, discussed exploring how obesity drugs can help patients with addiction.
7